A Better Vaccine is Needed
Our anthrax vaccine product candidates are being developed as next generation vaccines for the prevention of anthrax disease following inhalation of pathogen spores. Anthrax vaccines can be used as General Use Prophylactics (GUP) to establish immunity to anthrax disease prior to exposure to the pathogen, or as a Post-Exposure Prophylactic (PEP) for use with antibiotic therapy following exposure to the pathogen. Altimmune’s anthrax vaccine candidates are being developed for the PEP indication, however either candidate could also potentially be developed for the GUP indication.
Key Advantages of Anthrax Vaccines
SparVax-L is being developed as a second generation, highly purified recombinant anthrax vaccine that requires only two vaccinations for protection. SparVax-L is further differentiated by its remarkable stability profile that is well-suited for stockpiling in the Strategic National Stockpile.
Our NasoShield anthrax vaccine candidate is being developed as the ultimate anthrax vaccine. NasoShield is based on our RespirVec technology to provide protection following a single intranasal administration as opposed to multiple injections. Based on head-to-head results from studies performed in gold-standard preclinical models, NasoShield provided more rapid and consistent protection when compared to the currently approved anthrax vaccine, both potential key advantages for presumed use in a bioterrorism emergency.
Our anthrax vaccine candidates are being developed with support from the United States Government Department of Health and Human Services. SparVax-L is being developed with the support of the National Institute of Allergy and Infectious Diseases, and NasoShield is being developed with the support of the Biomedical Advanced Research and Development Authority.